Using the percentage of biopsy cores positive for cancer, pretreatment PSA, and highest biopsy Gleason sum to predict pathologic stage after radical prostatectomy: the center for prostate disease research nomograms
Kevin J Gancarczyk, Judd W. Moul(General Marble (Greece)), Douglas W. Soderdahl(Eisenhower Medical Center), Christopher J. Kane(University of California San Diego), Hongyu Wu(Qingdao University), Raymond Lance(Madigan Army Medical Center), J. A. Herring(Naval Medical Research Command), David G. McLeod(George Washington University), Dalton Baldwin(Malcolm Grow Medical Clinic), Jay T. Bishoff(Wilford Hall Ambulatory Surgical Center), John Foley(Princeton University), Leo Kusuda(Madigan Army Medical Center)
Cited by 79
Related Papers
Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2019|1.6k
Guideline for the Management of Clinically Localized Prostate Cancer: 2007 Update
|The Journal of Urology|2007|1.1k
Variation in the Definition of Biochemical Recurrence in Patients Treated for Localized Prostate Cancer: The American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel Report and Recommendations for a Standard in the Reporting of Surgical Outcomes
|The Journal of Urology|2007|845
Prostate Cancer, Version 1.2016
|Journal of the National Comprehensive Cancer Network|2016|656